Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246

Trial Profile

PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2019

At a glance

  • Drugs APR 246 (Primary) ; Carboplatin; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms PISARRO; PiSARRO
  • Sponsors Aprea
  • Most Recent Events

    • 02 Jul 2019 This trial has been completed in Sweden .
    • 01 Jul 2019 This trial has been completed in Spain .
    • 26 Jun 2019 This trial has been completed in France.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top